Why the Mobileye Bash Is So Muted

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Why the Mobileye Bash Is So Muted

© Thinkstock

[cnxvideo id=”625481″ placement=”ros”]Citron Research is an activist firm known for its infamous short positions over the years. This time Citron is setting its sights on Mobileye N.V. (NYSE: MBLY) after previously targeting NVIDIA Corp. (NASDAQ: NVDA) in the space. Citron released a report on Friday explaining its stance.

Eight weeks ago, NVIDIA was trading around $119, and at that point Citron recommended investors short the stock due to an overenthusiastic market. The firm gave a price target of close to $90 in the near term.

During this period the stock actually dropped closer to the $100 level, generating a solid return of about 16%.

[nativounit]

Now Citron is closing its position in NVIDIA and shifting its focus to Mobileye. The firm is shorting Mobileye with a short-term price target of $35, implying a downside of nearly 26% from the current price level. Citron pointed to a few statistics about Mobileye that help explain its position:

  • Valuation (NTM Period) is 36-times EBITDA.
  • LTM R&D as % of Enterprise Value is 0.7%.
  • R&D (LTM) totaled $65 million.
  • Free Cash Flow (FCF) totaled (LTM) $151 million (1.5% of EV).

Perhaps the most important point that Citron made was that insider sales for Mobileye have been massive over the past year. Insider sales at Mobileye since January 2016 have totaled over $250 million, which is over 350% of LTM R&D and over 150% of FCF. In the same time, NVIDIA insider sales totaled roughly $120 million, making up 9% of LTM R&D and 8% of FCF.

Keep in mind that Mobileye has a total market cap of just over $10 billion.

Shares of Mobileye were last seen down 2% at $47.12, with a consensus analyst price target of $56.95 and a 52-week trading range of $30.00 to $51.15.

NVIDIA was trading at $100.82, in a 52-week range of $31.04 to $120.92. The consensus price target is $113.59.

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Our $500K AI Portfolio

See us invest in our favorite AI stock ideas for free

Our Investment Portfolio

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618